BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 6, 2021
View Archived Issues
Positive phase II data published from GENETIC-AF study of bucindolol in patients with heart failure
Read More
Syros enters clinical supply agreement with Roche to evaluate SY-5609 as part of INTRINSIC study
Read More
Enanta nominates EDP-235 as clinical candidate for the treatment of COVID-19
Read More
Suzhou Zelgen Biosciences discovers G12C mutant GTPase KRAS inhibitors
Read More
Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent cereblon ligands
Read More
Hisun Accuray Therapeutics, Zhejiang Hisun Pharmaceutical present SHP-2 inhibitors
Read More
New thyroid hormone receptor agonists divulged by Eccogene
Read More
Aptahem reports positive preliminary results from GLP studies of Apta-1
Read More
Enrollment begins in phase II study of Stemedica's itMSCs in patients with COVID-19
Read More
Exicure provides updated interim data from phase Ib/II study of cavrotolimod
Read More
INPP5D inhibition reduces amyloid pathology in Alzheimer's disease model
Read More
First patient dosed in IMP-MEL study of PORT-2 for the treatment of melanoma and NSCLC
Read More
Clene provides topline data from REPAIR-PD and REPAIR-MS studies
Read More
MYMD-1 shows the ability to suppress cytokine storm in human cells
Read More
Nullifying necrosis: unfolded protein response inhibitors fight flesh-eating bacteria
Read More
Dosing begins in phase II portion of phase I/II trial of AKS-452
Read More
FDA places partial clinical hold on Aprea's myeloid malignancy programs
Read More
Enrollment starts in phase I study of ZYIL-1
Read More
Boehringer Ingelheim initiates phase I/II study of BI-765128 in diabetic macular ischemia
Read More
Labile iron pool radiotracer [18F]TRX can predict sensitivity to iron-targeted tumor therapies
Read More
GI Innovation begins patient enrollment in phase I/II study of GI-101
Read More
Enrollment ongoing in first-in-human study of [68Ga]-FF58
Read More